Position of the Transparency Council – Fruzaqla (fruquintinib)
At its meeting on 22 April 2025, the Transparency Council adopted position No. 45/2025 on the evaluation of the drug Fruzaqla (fruquintinib) under the drug program B.4 “Treatment of patients with colorectal cancer (ICD-10: C18–C20)”